Hemangioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
:*[[Interferon]] | :*[[Interferon]] | ||
:*[[Vincristine]] | :*[[Vincristine]] | ||
::*These agents have also been used for: | ::*These agents have also been used for:<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
:::*Multifocal disease | :::*Multifocal disease | ||
:::*Visceral involvement | :::*Visceral involvement | ||
| Line 22: | Line 23: | ||
*The indication spectrum includes vascular tumors including hemangiomas. | *The indication spectrum includes vascular tumors including hemangiomas. | ||
===Propranolol=== | ===Propranolol=== | ||
*A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years. | *A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*Propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease. | *Propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease. | ||
*Numerous studies demonstrating the success of propranolol for shrinking hemangiomas | *Numerous studies demonstrating the success of propranolol for shrinking hemangiomas | ||
Revision as of 20:31, 17 November 2015
|
Hemangioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemangioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemangioma medical therapy |
|
Risk calculators and risk factors for Hemangioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Medical Therapy
- Medical and surgical options are available for the treatment of “problematic” hemangiomas.[1]
- Medical management includes one or more systemic therapies.
- For massive and life-threatening disease:[1]
-
- These agents have also been used for:[1]
- Multifocal disease
- Visceral involvement
- Segmental distribution
- Airway obstruction
- Periorbital lesions
Intense pulsed light
- IPL flash lamps emit broadband polychromatic high-intensity light in the wavelength spectrum ranging 515-1200nm.[2]
- They target vessels at various depths inside the skin.
- The effect relies on selective photothermolysis.
- The indication spectrum includes vascular tumors including hemangiomas.
Propranolol
- A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years.[1]
- Propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease.
- Numerous studies demonstrating the success of propranolol for shrinking hemangiomas
- Over ninety percent of patients have dramatic reduction in the size of their hemangiomas as early as 1-2 weeks following the first dose of propranolol.
- Dosing for propranolol in treating hemangiomas is recommended to be 2-3 mg/kg separated into two or three-times-a-day regimens.
- These doses are dramatically below the concentration employed for cardiovascular conditions in children.
References
- ↑ 1.0 1.1 1.2 1.3 Richter, Gresham T.; Friedman, Adva B. (2012). "Hemangiomas and Vascular Malformations: Current Theory and Management". International Journal of Pediatrics. 2012: 1–10. doi:10.1155/2012/645678. ISSN 1687-9740.
- ↑ Caucanas, Marie; Paquet, Philippe; Henry, Frédérique; Piérard-Franchimont, Claudine; Reginster, Marie-Annick; Piérard, Gérald E. (2011). "Intense Pulsed-Light Therapy for Proliferative Haemangiomas of Infancy". Case Reports in Dermatological Medicine. 2011: 1–5. doi:10.1155/2011/253607. ISSN 2090-6463.